comparison was applied to compare entecavir with interferon and the combination of interferon and lamivudine. When compared with lamivudine, the combination of interferon and lamivudine yielded the best effi cacy which was about two times more likely to increase HBeAg seroconversion rate (OR = 2.38, 95% CI = 1.21-4.06) than entecavir (OR = 0.98, 95% CI = 0.56-1.44) and interferon (OR = 1.17, 95% CI = 0.44-2.24). In addition, when compared with either interferon or entecavir, interferon plus lamivudine was about two to three times more likely to enhance HBeAg seroconversion rate with the OR of 2.48 (95% CI = 1.05-4.92) or 2.71 (95% CI = 1.13-5.33), respectively. CONCLU-SIONS: There was a signifi cant increase in HBeAg seroconversion rate in patients with HBeAg positive CHB receiving the combination of interferon and lamivudine compared with lamivudine, entecavir and interferon. OBJECTIVES: To evaluate clinical outcome and direct medical cost using Kabiven and traditional peripheral partenteral nutrition for postoperative patients in ICU. METHODS: This is a restrospective study. Medical records of postoperative patients in ICU were reviewed by clinical pharmacists from July 2008 to July 2009. The retrieved patients were divided into two groups, kabiven group (n = 49) and separate bottle group (SB) (n = 50). Patients, characteristics were evaluated and compared between two groups. The measured outcomes were the clinical effectiveness and direct medical costs. One way ANOVA were used for analysis. RESULTS: There were no statistically signifi cance difference in patients, characteristics between two groups. Survival rate was higher in kabiven group than in SB group (40% vs. 31%, respectively). The length of stay in hospital in kabiven group was longer than in SB group (47.51 ± 38.63 vs. 31.86 ± 21.99 days, respectively; P < 0.015). Total direct medical costs of survivors in kabiven group was more expensive than in SB group ($11,976.9 vs. $9574.9, respectively). CONCLUSIONS: Although the direct medical cost of kabiven group were higher than SB group, use of kabiven is likely to improve mortality rate of postoperative patients in ICU. OBJECTIVES: Heptatitis B is prevalent in South Korea and chronic hepatitis B (CHB) infection is an important public health issue due to its potential to evolve to cirrhosis, hepatocellular carcinoma. This study estimated the direct medical cost of CHB-related disease states in South Korea and compared the cost of South Korea with that of USA, Australia and China. It also aimed to analyze the impact of three therapeutic alternatives for CHB by Budget Impact Analysis (BIA). METHODS: Dynamic budget impact analysis was conducted based on a Markov model for 5 years. Three treatment scenarios were selected as follows: fi rst-line treatment of lamivudine, second-line combination treatment of lamivudine and adefovir on the development of drug resistance, fi rst-line treatment of lamivudine, second-line treatment of entecavir 1.0 mg on the development of drug resistance, fi rst-line treatment of entecavir 0.5 mg, second-line treatment of adefovir on the development of drug resistance, no treatment available. RESULTS: The BIA results of scenario A, B, C and no treatment were 75, 74.7, 85.9, and 48.1 billion Korean Won (KRW), respectively. The results were relatively insensitive to the TP and sensitive to the number of treated patients based on sensitivity analyses. The costs of annual direct medical costs in South Korea were 23.2%~65.8%, 16.2%~59.1%, and 75.8%~381.7% of the annual direct medical costs in the United States, Australia, and China. CONCLUSIONS: Scenario C (fi rst-line treatment of entecavir 0.5 mg, second-line treatment of adefovir) was found to be 10.9~11.2 billion KRW more expensive than scenario A and B from payer's perspective. In South Korea, the direct medical costs of CHB-related diseases are cheaper than the United States and Australia. It suggests that such factors as the difference of GNP (Gross National Product), health-care system and others contribute to the difference of the direct medical costs.
PGI5 EVALUATION OF OCTREOTIDE COST AFTER PHARMACEUTICAL CARE IMPLEMENTATION AT SURGICAL WARD
Sawatpanit A Department of Pharmacy, Roi-et Hospital, Muang, Thailand, Thailand OBJECTIVES: Our objective was to compare cost saving before and after of pharmaceutical care implementation and Octreotide use evaluation at surgical ward. METHODS: This study was conducted during October 1, 2008 to April 30, 2009 . The research instruments were octreotide use criteria with approval by surgical staffs. Pharmacist reviewed and evaluated the medical chart in order to identify medication related problems by focusing on medication regimens. Medication related problems were classifi ed into three categories: inappropriate route, inappropriate duration and inappropri-ate indication of administration. Cost saving was based on drug costs. The pre-and post-pharmaceutical care implementation and octreotide use evaluation results were compared and analyzed with descriptive retrospective statistics and paired t-test at 95 % signifi cant level. RESULTS: There were 302 patients received Octreotide. One hundred ninety-three patients (63.9%) were prescribed Octreotide appropriately. Medication related problems were found in 109 patients (36.1%). The most frequent problems were inappropriate duration (44.95%), inappropriate indication (34.86%) and inappropriate route of administration (20.18%). The cost of Octreotide use for inappropriate duration, inappropriate indication and inappropriate route of administration were signifi cantly decreased after pharmaceutical care implementation 3,062,160 versus 1,946,400 baht, 657,000 versus no money, and 919,800 versus 226,800 baht, respectively (P < 0.005). The total cost of Octreotide use was 9,529,950 baht reducing to 7,015,008 baht after pharmaceutical care implementation with statistically signifi cant (P < 0.005). CONCLUSIONS: The implementation of pharmaceutical care and evaluation of Octreotide use resulted in signifi cant cost saving. The drug utilization program, consisting of deriving quality criteria for prescribing, structured order form and good cooperation between physicians and pharmacists with strong support of the therapeutics committee, was an effective strategic approach to promote rational drug use and develop Octreotide use guidelines.
GASTROINTESTINAL DISORDERS -Patient-Reported Outcomes Studies

PGI7 THE EFFECT OF ANTIVIRAL THERAPY ON QUALITY OF LIFE IN CHRONIC HEPATITIS PATIENTS: A SYSTEMATIC REVIEW
Pansang S, Maphanta S Naresuan University, Muang, Phitsanulok, Thailand OBJECTIVES: Chronic viral hepatitis B and C are treated primarily with interferon (IFN) and/or nucleotide analogs e.g., ribavirin (RBV) which produced sustained viral response in more than 50% of treated patients. However, the combination may also cause numerous side effects that could reduce patients' quality of life (QoL). To determine the effect of antiviral therapy on QoL of chronic hepatitis patients. METHODS: Key words were "Quality of life" AND "chronic hepatitis" AND "antiviral therapy," "lamivudine," "ribavirin," "adefovir," "entacavir," "telbivudine" "tenofovir" and were searched from PubMed and EMBASE database. Study selection criteria were original articles in which patients received antivirals for chronic hepatitis B or C, and assessed QoL. The comparators were no treatment, placebo or at least one other antiviral. Studies that involved co-HIV infection were excluded. One independent researcher reviewed titles and abstracts to determine relevance. Study design, dose, duration, baseline values, and QoL scores were extracted. RESULTS: Six studies met all the criteria. Four QoL instruments were used in those studies. SF 36 and HQLQ questionnaires were the most common. Patients who received peginterferonμ-2a plus placebo reported better QoL than peginterferonμ-2a plus ribavirin during the treatment (week 2-48) in two RCTs. However, the results were less consistent and less prominent during the week of 72 and 96. The effect seemed to be non-dose related. One RCT showed that interferon μ plus ribavirin produced better QoL than untreated when measured with EQ 5D questionnaire, but it did not reach statistical signifi cant. In similarly, peginterferone μ-2a plus ribavirin did not showed a signifi cant better Fatigue severity scale at week 72 when compared with peginterferonμ-2a plus placebo. CONCLUSIONS: Antiviral therapy (interferon plus ribavirin) reduced QoL only during the treatment. Results seemed to be consistent across all four types of QoL questionnaires.
GASTROINTESTINAL DISORDERS -Health Care Use & Policy Studies
PGI8 ANTIBIOTIC PRESCRIBING PRACTICES OF PRIMARY CARE PRESCRIBERS FOR DIARRHEA NI NEW DELHI, INDIA
Kotwani A 1 , Roy Chaudhury R 2 , Holloway K 3 1 Vallabhbhai Patel Chest Institute, Univ of Delhi, Delhi, India; 2 Indraprastha Apollo Hospitals, New Delhi, India; 3 World Health Organisation, Geneva, Switzerland OBJECTIVES: This study was conducted to obtain information on current prescribing rates of antibiotics in diarrhea, a condition where misuse of antibiotics is common. In the absence of community-based databases on antibiotic use in developing countries recently a methodology was established for surveillance of antibiotic use at New Delhi by conducting 'Exit Interviews' of the patients. METHODS: Antibiotic use data was collected from public and private sector facilities from four residential localities around a tertiary care hospital where the antibiotic resistance work was being conducted. All the 10 public sector facilities (eight primary and two secondary health cares) situated in the study area under Delhi government were enrolled. For private sector, 20 willing and cooperative general practitioners and specialists practicing in the chosen areas were selected. Patients after consultation with prescriber were asked if they had diarrhea but without blood. Patients with diarrhea were enrolled for exit interview and his/her prescription was monitored. Antibiotic use data was collected per month over 1 year (December 2007 -November 2008 . The percentage of patients receiving antibiotic and pattern of consumption for various antibiotics was analyzed. RESULTS: At public facilities 43% (171/398) and at private facilities 69% (76/110) of patients with diarrhea were prescribed at least one antibiotic. Main antibiotic class that was prescribed in public and private sector was fl uoroquinolones (89% and 94%); 4th Asia-Pacifi c Abstracts A533 the second group in public sector was cephalosporins (4%) and in private sector were penicillins (3%). In private sector pediatricians prescribed antibiotics to 52% (17/33) of children with diarrhea and fl uoroquinolone group was prescribed to all. At public facilities, main members from fl uoroquinolones were norfl oxacin, followed by ofl oxacin and ciprofl oxacin. At private clinics, it was ofl oxacin followed by ciprofl oxacin. Pediatricians mainly prescribed ofl oxacin, followed by norfl oxacin. CONCLUSIONS: This study clearly shows over-prescription and irrational use of antibiotics for treatment of diarrhea that warrants interventional strategies.
HEALTH CARE USE & POLICY STUDIES -Consumer Role in Health Care
PHP1 A STUDY EVALUATING PATTERN OF NON-PRESCRIPTION PURCHASE BY CONSUMERS FROM COMMUNITY PHARMACIES IN MALAYSIA
Ahmad Hassali MA, Shafi e AA, Mohamad Yahaya AH Universiti Sains Malaysia, Penang, Penang, Malaysia OBJECTIVES: To analyze the pattern of non-prescription medicine purchase by consumer from community pharmacies in Malaysia. METHODS: A cross-sectional survey comprised a sample of 1799 community pharmacy consumers was conducted nationwide. A pharmacy "exit survey" was developed and administered to pharmacy consumers of randomly selected community pharmacies in order to collect information on the purchased nonprescription medicine(s) including its costs. In this study, the nonprescription medicine defi nition was adopted from the Malaysian Poison Act 1952. Data were analyzed using Kruskal-Wallis, Mann-Whitney, chi-square and Spearman correlation test in SPSS v15. RESULTS: A total of 2175 nonprescription medicines were purchased by consumers interviewed in 2 weeks study period. The total cost estimated for all item purchased was RM41,000 (USD13,000). About 39.6% of the purchased items are listed under scheduled poison, 45.5% were unscheduled poison and 12.5% are those listed as traditional and complementary medicine. Medicine for alimentary tract and metabolism, musculo-skeletal system and respiratory system as categorized by Anatomical Therapeutic Coding were among the highest purchased medicine. Factors such as gender especially females, area of origin especially those from urban area, ethnicity especially chinese consumers and those earning high income level shows to have a signifi cant infl uence in the spending for non-prescription medicine purchasing. This study also showed purchasing for non-prescription medicine signifi cantly increased as aging. Consumers spent signifi cantly more on noncontrolled medicine such as vitamins and herbal preparations compared to other categories of medicines (χ 2 = 185.07, P < 0.001). CONCLUSIONS: The evaluation on pattern of nonprescription medicine purchasing in Malaysia reveals that consumers in Malaysia are able to spend money for buying medicines to treat minor ailments and practice of self-medication. The socio-demographic factors that associated with non-prescription medicine purchase will serve as useful information for policymakers and also the pharmaceutical industry for future development in rational medicine use education among consumers in the country.
HEALTH CARE USE & POLICY STUDIES -Disease Management
PHP3 RARE DISEASES, ORPHAN DRUGS, AND THE LEGISLATION IN CHINA
Zhang YJ 1 , Guo JJ 1 , Wang JB 2 1 University of Cincinnati, Cincinnati, OH, USA; 2 People's Liberation Army 309 Hospital, Beijing, China OBJECTIVES: Public awareness of rare diseases and access to orphan drugs is increasing in China. The purpose of this study was to review the epidemics of rare diseases, the access to orphan drug treatments, and its related legislation in China. METHODS: A systematic literature review was performed based on published articles, government Websites, and some Internet search engines. The rare diseases, available orphan drug treatments, and related legislations in China were reviewed. Some comparisons related to these topics were discussed between China and developed countries like the United States. RESULTS: With conservative estimation, there are at least 10 million Chinese people living with rare diseases. The frequently mentioned rare diseases in China include osteogenesis imperfecta, neuromuscular diseases, Fabry disease, Gaucher disease, phenylketonurias, hemophilia A and B, lymphangioleiomyomatosis, albinism, and acromegaly. Patients with rare diseases in China generally lack the access to appropriate health care especially the orphan drug therapies. While we observed the signifi cant impact of Orphan Drug Act on new drug developments and rare disease treatments in developed countries, there is little new orphan drug designated or developed in China. There are very few imported orphan drugs in the Chinese market. A grouping number of Chinese rare-disease organizations such as the China Albinism Association and the China-Dolls Care and Support Association are working with government on a new legislation about health care assesses and insurance policy for rare diseases. CONCLUSIONS: Public and governmental concerns about rare diseases have been boosted in China. Their available treatments and legislation in China are lagging far behind the United States, the European Union, Australia, Singapore, Japan, and South Korea. An effective public health insurance and public policy are needed for rare disease treatments and orphan drug developments.
HEALTH CARE USE & POLICY STUDIES -Drug/Device/Diagnostic Use & Policy
PHP4 EFFECTIVENESS OF TWO POLICIES TO REDUCE DIPHENOXYLATE CONSUMPTION IN IRAN
Jaberi Doost M 1 , Abdollahiasl A 1 , Safavi Homami N 2 , Farshchi A 1 , Ghiasi G 1 , Anabi M 1 1 Tehran University of Medical Sciences, Tehran, Iran; 2 Ministry of Health, Tehran, Iran OBJECTIVES: Iran had one of the highest uses of Diphenoxylate in the world in 2008. About 1 billion tablets of Diphenoxylate 2.5 mg have been consumed during that year. In the last months of 2008 the ministry of health tried some policies to reduce the consumption. One was rationing in production the other was doubling the price of 10 medicines which likely were abused including Diphenoxylate. This study tries to show the effectiveness of these two interventions by evaluating monthly consumption of Diphenoxylate during recent 5 years ended to March 2010. METHODS: Data were gathered from the distributors and wholesalers of this medicine from whole the country. These data were crosschecked with importation data in the ministry of health. We did a time trend analysis on tabulated data. RESULTS: There are some variations in monthly use of Diphenoxylate but the trend shows a signifi cant decrease after the rationing in production. In 2009 the average consumption has reached to less than 650 millions of tablet, four Defi ned Daily Dose per 1000 Inhabitants per day which shows 36% decrease in comparison with the previous year. In second half of 2009 and fi rst 2 months of 2010 after the second intervention, there is no signifi cant change in the trend. CONCLUSIONS: Although the high consumption of opiates in Iran is a multi factorial phenomena but this study shows; the fi rst intervention has been able to control the abuse of Diphenoxylate due to the reduction of market supply and decrease in Diphenoxylate's unoffi cial promotion. Considerable result wasn't seen in the second approach. The user price of Diphenoxylate tablet in Iran is too cheap and doubling the price doesn't work at all. A signifi cant tax mark-up and increasing the price based on label use may affect on affordability of Diphenoxylate's abuse.
PHP5 THE ESSENTIAL MEDICINE SYSTEM IN CHINA: STRATEGIES AND CHALLENGES
Yang L Peking University, Beijing, China OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospitals were encouraged to make their own incomes with the aim of mobilizing medical workers and improving hospital effi ciency. Less government funding resulted in deficits for public health institutions, which forced hospitals to generate their own revenue by aggressively selling drugs, especially expensive drugs. There are challenges in poor drug access, drug procurement, rising drug costs and fi nancial risk. In March 2009, China fi nally unveiled its health care reform plan. The Chinese government announced it will institute an essential medicine system within 3 years to drive down prescription costs and quell public complaints of limited accessibility of medicines. This study is to describe the strategies to build the essential medicine system at the provincial level in China and challenges associated with promoting it. METHODS: Key actors, their power, views and interactions will be assessed using appropriate qualitative methods as these are best suited to understanding complexity, richness of material and motivations of actors, and using a policy analysis to know the key governance issues and underlying relationships affecting its success or failure. RESULTS: The system includes a list of essential medicines that would be produced and distributed under government control and supervision, and it should be used at all public health facilities at grassroots levels from 2009. The central government will set reference prices, based on which, provincial governments set the purchase prices of the drugs in their jurisdiction. Public medical and health facilities at the grassroots levels should sell the drugs at the purchase prices. These generally involve the transfer for a fi xed fee from the local MOH to the health service center/post in exchange for the removal of retail mark up, which couldn't offset the profi t of selling drugs. CONCLUSIONS: The provider incentive is very crucial for building an essential medicine system, which is dependent upon the reimbursement system.
PHP6
RECOMMENDATIONS FOR A BIOLOGICS-SPECIFIC PRICING SYSTEM IN CHINA
Yao W, Shao R, Chen Y, Chang F Research Center of Pharmaceutical Industry Development, China Pharmaceutical University, Nanjing, Jiangsu, China OBJECTIVES: The pricing system for chemical drugs is currently applied to biologics in China as no specifi c pricing system for biologics exists yet in China. This practice does not fully refl ect the characteristics of biologics and may potentially prevent the launch of biologics in China and discourage the development of biologics. The objective of this study is to explore adequate pricing mechanisms for biologics. METHODS: Both primary research (fi eld research, expert interviews, surveys) and secondary research were conducted to determine the key determinants of the price of biologics and understand the complexity of R&D, manufacturing and distribution required for biologics. Statistical analyses were performed to assess the relationship of key determinants and the price. Government and manufacturer behavior were modeled using game theory to demonstrate prerequisites of implementing 'differential pricing'. RESULTS: A different pricing system is required for biologics given its unique characteristics. Certain characteristics (including special clinical value, target-specifi c R&D
